The PSC Category AN82, "R&D- Medical: Aids Research (Applied Research/Exploratory Development)," focuses on research and development activities specifically targeting medical interventions and treatments related to AIDS/HIV. This category encompasses applied scientific research and early-stage technological development aimed at understanding, preventing, and potentially treating HIV/AIDS. The work includes laboratory investigations, clinical research protocols, diagnostic technology development, potential therapeutic approaches, and exploratory medical innovations directly addressing AIDS-related medical challenges. No specific contract award details were provided in the original data, so a comprehensive summary of recent awards cannot be constructed. A typical federal contract in this category would likely involve research institutions, medical universities, pharmaceutical research organizations, and specialized biomedical research firms conducting focused scientific investigations. Anticipated contract values would range from smaller grants of $100,000 to multi-million dollar comprehensive research programs, with durations typically spanning 1-3 years. Funding would most likely originate from agencies such as the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), or Department of Health and Human Services (HHS). No specific contract opportunities were detailed in the provided information. Potential opportunities in this PSC category would likely solicit cutting-edge medical research proposals focused on HIV/AIDS prevention, treatment development, epidemiological studies, and advanced diagnostic methodologies. Research sites would typically be located at academic medical centers, dedicated research hospitals, university laboratories, and specialized medical research facilities across the United States. Potential solicitations would emphasize innovative approaches to understanding HIV transmission, developing therapeutic interventions, and exploring potential vaccination strategies.
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Last Date To Order (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
266965310 | No Data From D And B | $5.7m | 2/25/02 | Not listed | 2/25/02 | |
223971036 |
--
| BBI Biotech Research Laboratories Incorporated | $0 | 8/15/01 | 7/15/02 | 8/15/01 |
266975323 |
--
| Seamon Corp | $0 | 3/15/98 | 8/15/02 | 3/15/98 |
266965311 |
--
| University Of Washington | $4.7m | 8/15/01 | Not listed | 10/31/05 |
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Completion Date (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
Definitive Contract HHSN272201300015C | Pulmokine, Inc. | $225.0k | 9/16/13 | 1/15/16 | 9/28/15 | |
Purchase Order 00266199207B266905055 |
--
| Starks Associates Inc. | $0 | 7/15/92 | Not listed | 7/15/92 |
Purchase Order 00266199303B266905065 |
--
| University Of Washington | $0 | 3/15/93 | 1/15/95 | 3/15/93 |
Purchase Order 00266199403B266905047 |
--
| Clinical Directors Network, Inc. | $0 | 3/15/94 | 10/15/94 | 3/15/94 |
Definitive Contract 00266200206D266025461 | University Of Maryland | $106.6m | 6/1/02 | 3/30/09 | 9/8/11 |